GFAP and Alzheimer disease: Our findings indicated that plasma p-tau217, GFAP, p-tau181, and NfL detected by both Simoa and LiCA assays exhibited comparable efficiency in the entire AD spectrum in identifying individuals with Aβ PET positivity.